| Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer F Schettini, N Chic, F Brasó-Maristany, L Paré, T Pascual, B Conte, ... NPJ breast cancer 7 (1), 1, 2021 | 369 | 2021 |
| Frequency and spectrum of PIK3CA somatic mutations in breast cancer O Martínez-Sáez, N Chic, T Pascual, B Adamo, M Vidal, B González-Farré, ... Breast cancer research 22, 1-9, 2020 | 239 | 2020 |
| Current and future management of HER2-positive metastatic breast cancer O Martínez-Sáez, A Prat JCO oncology practice 17 (10), 594-604, 2021 | 165 | 2021 |
| HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: a systematic review and meta-analysis F Schettini, T Pascual, B Conte, N Chic, F Brasó-Maristany, P Galván, ... Cancer treatment reviews 84, 101965, 2020 | 122 | 2020 |
| Targeting HIF-2 α in clear cell renal cell carcinoma: A promising therapeutic strategy O Martínez-Sáez, PG Borau, T Alonso-Gordoa, J Molina-Cerrillo, ... Critical reviews in oncology/hematology 111, 117-123, 2017 | 122 | 2017 |
| Correlative biomarker analysis of intrinsic subtypes and efficacy across the MONALEESA phase III studies A Prat, A Chaudhury, N Solovieff, L Paré, D Martinez, N Chic, ... Journal of Clinical Oncology 39 (13), 1458, 2021 | 104 | 2021 |
| Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade F Brasó-Maristany, G Griguolo, T Pascual, L Paré, P Nuciforo, ... Nature communications 11 (1), 385, 2020 | 82 | 2020 |
| Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. npj Breast Cancer. 2021; 7: 1 F Schettini, N Chic, F Brasó-Maristany, L Paré, T Pascual, B Conte, ... PUBMED, 0 | 36 | |
| Gene expression profiles of breast cancer metastasis according to organ site F Brasó‐Maristany, L Paré, N Chic, O Martínez‐Sáez, T Pascual, ... Molecular oncology 16 (1), 69-87, 2022 | 31 | 2022 |
| Inhibition of peripheral synthesis of serotonin as a new target in neuroendocrine tumors J Molina-Cerrillo, T Alonso-Gordoa, O Martínez-Sáez, E Grande The Oncologist 21 (6), 701-707, 2016 | 29 | 2016 |
| Emerging use of everolimus in the treatment of neuroendocrine tumors P Gajate, O Martínez-Sáez, T Alonso-Gordoa, E Grande Cancer management and research, 215-224, 2017 | 25 | 2017 |
| Tumour lysis syndrome in solid tumors: clinical characteristics and prognosis F Caravaca-Fontán, O Martínez-Sáez, S Pampa-Saico, ME Olmedo, ... Medicina Clínica (English Edition) 148 (3), 121-124, 2017 | 22 | 2017 |
| SOLTI-1805 TOT-HER3 study concept: a window-of-opportunity trial of patritumab deruxtecan, a HER3 directed antibody drug conjugate, in patients with early breast cancer T Pascual, M Oliveira, E Ciruelos, M Bellet Ezquerra, C Saura, J Gavilá, ... Frontiers in Oncology 11, 638482, 2021 | 21 | 2021 |
| Safety and oncological outcomes of bevacizumab therapy in patients with advanced colorectal cancer and self-expandable metal stents V Pacheco-Barcia, R Mondejar, O Martínez-Sáez, F Longo, JA Moreno, ... Clinical colorectal cancer 18 (3), e287-e293, 2019 | 21 | 2019 |
| Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer A Prat, F Brasó-Maristany, O Martínez-Sáez, E Sanfeliu, Y Xia, M Bellet, ... Nature communications 14 (1), 1157, 2023 | 17 | 2023 |
| Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy O Martínez-Sáez, T Pascual, F Brasó-Maristany, N Chic, ... NPJ breast cancer 7 (1), 8, 2021 | 16 | 2021 |
| Translating new data to the daily practice in second line treatment of renal cell carcinoma: the role of tumor growth rate E Grande, O Martínez-Sáez, P Gajate-Borau, T Alonso-Gordoa World Journal of Clinical Oncology 8 (2), 100, 2017 | 16 | 2017 |
| Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. NPJ Breast Cancer. 2021; 7 (1): 1 F Schettini, N Chic, F Brasó-Maristany, L Paré, T Pascual, B Conte, ... Epub 2021/01/06. https://doi. org/10.1038/s41523-020-00208-2 PMID: 33397968, 0 | 15 | |
| Prognostic and predictive role of the PI3K–AKT–mTOR pathway in neuroendocrine neoplasms P Gajate, T Alonso-Gordoa, O Martínez-Sáez, J Molina-Cerrillo, E Grande Clinical and Translational Oncology 20, 561-569, 2018 | 14 | 2018 |
| Primary sarcomatoid tumor of the bladder: a different entity but the same approach? J Molina-Cerrillo, O Martínez-Sáez, T Alonso-Gordoa, P Tirado-Zambrano, ... Clinical Genitourinary Cancer 13 (6), 493-498, 2015 | 12 | 2015 |
